MLTX
MoonLake ImmunotherapeuticsPre-market10.41−0.27 −2.53%USD
NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 10.48 +0.67%
Open
10.70
Prev close
10.68
Day range
10.3610.84
52-week range
8.8023.29
Volume
2.41M1.64×
Mkt cap
885.96M
P/E ttm
—
Fwd P/E
-3.13
EPS ttm
-3.83
Div yield
0.00%
Earnings
Aug 10, 2026
From 52w high
−55.30%
MLTX earnings and estimates
MLTX Next Report
Yahoo Finance · Nasdaq
Report date
Thu, Nov 5
Before the open · estimated
EPS consensus
$−0.78
range −0.88 – −0.66
EPS growth vs year ago
+29.0%
year ago −1.10
Revenue consensus
$0
0.0% vs year ago
Options-implied move
±19.6%
by Nov 20 · ATM straddle
Past 4 reactions
±5.0%
average move · beat 2 of 4
EPS: Actual vs Estimate
Price Reaction
close before → close after the report
Recent Reports
| Quarter ending | Reported | EPS | Estimate | Surprise | Revenue | Next session | Five sessions |
|---|---|---|---|---|---|---|---|
| Jun '26 | Aug 10, 2026 BMO | −0.84 | −0.90 | +6.20% | $0 | −5.1% | −9.8% |
| Mar '26 | May 11, 2026 BMO | −0.98 | −0.92 | −6.38% | $0 | +10.4% | +2.9% |
| Dec '25 | Feb 25, 2026 BMO | −0.92 | −0.94 | +2.60% | $0 | +0.1% | −2.8% |
| Sep '25 | Nov 5, 2025 BMO | −1.10 | −0.92 | −20.17% | $0 | +4.5% | +16.0% |
Consensus Estimates and Revisions
| Period | EPS | Low · range · high | Growth | Revenue | Growth | 30d ago | 90d ago | Up / down (30d) |
|---|---|---|---|---|---|---|---|---|
| Current quarter Sep 2026 | −0.78 | −0.88−0.66 | +29.0% | $0 | 0.0% | −0.78 0.0% | −0.92 +15.5% | 6 / 0 |
| Next quarter Dec 2026 | −0.81 | −1.01−0.67 | +11.5% | $0 | 0.0% | −0.81 0.0% | −0.90 +9.6% | 4 / 2 |
| Current year Dec 2026 | −3.38 | −3.67−2.91 | +4.3% | $0 | 0.0% | −3.38 0.0% | −3.84 +12.0% | 5 / 1 |
| Next year Dec 2027 | −3.33 | −4.15−2.59 | +1.6% | $19.04M | 0.0% | −3.33 0.0% | −3.43 +3.0% | 5 / 1 |
The change columns show how the consensus has moved since then; steady upward revisions often precede beats. Ranges place the consensus between the lowest and highest analyst estimate.
Forward EPS Forecasts
Nasdaq · Zacks consensus
Quarterly
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Sep 2026 | −0.77 | −0.88−0.70 | 4 | 0 / 0 |
| Dec 2026 | −0.81 | −0.93−0.69 | 4 | 0 / 0 |
| Mar 2027 | −0.63 | — | 1 | 0 / 0 |
| Jun 2027 | −0.72 | — | 1 | 0 / 0 |
| Sep 2027 | −0.76 | — | 1 | 0 / 0 |
Fiscal years
| Fiscal period | Consensus | Low · range · high | Analysts | Up / down (4w) |
|---|---|---|---|---|
| Dec 2026 | −3.34 | −3.54−3.14 | 4 | 0 / 0 |
| Dec 2027 | −3.41 | −4.20−2.67 | 5 | 0 / 0 |
| Dec 2028 | −0.96 | — | 1 | 0 / 0 |
| Dec 2029 | 0.70 | — | 1 | 0 / 0 |
Reactions run from the last close before a report to the first close after it (an after-the-close report is measured to the next day's close). The implied move is the at-the-money straddle for the first expiry after the report, the same rule as the bot's lgf emove.